Vbi Vaccines Inc buy melinda
Start price
10.08.18
/
50%
?1.81
Target price
01.10.18
€2.62
Performance (%)
24.38%
End price
01.10.18
€2.26
Summary
This prediction ended on 01.10.18 with a price of €2.26. The prediction had a final performance of 24.38%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Vbi Vaccines Inc | - | - | - | - |
| iShares Core DAX® | -1.424% | 8.918% | 7.311% | 49.214% |
| iShares Nasdaq 100 | 3.274% | 16.275% | 36.651% | 97.344% |
| iShares Nikkei 225® | 1.745% | 16.239% | 46.602% | 64.976% |
| iShares S&P 500 | 1.447% | 10.913% | 27.166% | 68.765% |
Comments by melinda for this prediction
In the thread Vbi Vaccines Inc diskutieren
SecteurRecherche biotechnologique et médicale Agenda 12/11 Publication de résultats
VBI Vaccines, Inc. is a biopharmaceutical company, which develops vaccines for infectious disease and immuno-oncology.
Its pipeline includes Sci-B-Vac, CMV Vaccine, GBM Immunotherapy, MB Immunotherapy, and Zika Vaccine.
The company was founded on July 9, 2015 is headquartered in Cambridge, MA.
Nombre d'employés : 103 personnes.